Article
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
JAMA oncology - 1 Nov 2015
Dinan Michaela A, Mi Xiaojuan, Reed Shelby D, Lyman Gary H, Curtis Lesley H
Abstract excerpt
IMPORTANCE: Guidelines recommend consideration of chemotherapy for most patients with early-stage, estrogen receptor-positive, invasive breast cancer in the absence of additional prognostic information. The 21-gene recurrence score (RS) assay has been shown in limited academic settings to reduce physician recommendations for adjuvant chemotherapy. Associations between the adoption of the assay and receipt of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
